

CXCL9 (Human) ELISA Kit

Catalog Number KA0555

96 assays

Version: 05

Intended for research use only



Table of Contents

Int	roduction	3
	Intended Use	3
	Background	3
	Principle of the Assay	3
Ge	eneral Information	4
	Materials Supplied	4
	Storage Instruction	4
	Materials Required but Not Supplied	4
	Precautions for Use	5
As	say Protocol	6
	Reagent Preparation	6
	Sample Preparation	7
	Assay Procedure	7
Da	ta Analysis	9
	Calculation of Results	9
	Performance Characteristics	9
Re	sources	10
	Reference	10
	Plate Layout	11



Introduction

Intended Use

Sandwich ELISA kit for quantitative detection of human CXCL9 in cell culture supernates, cell lysates, serum and plasma (heparin, EDTA).

Background

Chemokine (C-X-C motif) ligand 9 (CXCL9) is a small cytokine belonging to the CXC chemokine family that is also known as Monokine induced by gamma interferon (MIG). CXCL9 is a T-cell chemoattractant, which is induced by IFN-γ. It is closely related to two other CXC chemokines called CXCL10 and CXCL11, whose genes are located near the gene for CXCL9 on human chromosome 4.^{1,2} CXCL9, CXCL10 and CXCL11 all elicit their chemotactic functions by interacting with the chemokine receptor CXCR3.³ The standard product used in this kit is recombinant human CXCL9, consisting of 103 amino acids with the molecular mass of 11.7KDa.

Principle of the Assay

The CXCL9 (Human) ELISA Kit was based on standard sandwich enzyme-linked immune-sorbent assay technology. A monoclonal antibody from mouse specific for CXCL9 has been precoated onto 96-well plates. Standards (Expression system for standard: E.coli, Immunogen sequence: T23-T125) and test samples are added to the wells, a biotinylated detection polyclonal antibody from goat specific for CXCL9 is added subsequently and then followed by washing with PBS or TBS buffer. Avidin-Biotin-Peroxidase Complex was added and unbound conjugates were washed away with PBS or TBS buffer. HRP substrate TMB was used to visualize HRP enzymatic reaction. TMB was catalyzed by HRP to produce a blue color product that changed into yellow after adding acidic stop solution. The density of yellow is proportional to the human CXCL9 amount of sample captured in plate.



General Information

Materials Supplied

List of component

Component	Amount		
96-well plate precoated with anti- human CXCL9 antibody	96 (8x12) wells		
Lyophilized recombinant human CXCL9 standard	10 ng × 2		
Biotinylated anti-human CXCL9 antibody: dilution 1:100	130 µL		
Avidin-Biotin-Peroxidase Complex (ABC), dilution 1:100	130 μL		
Sample diluent buffer	30 mL		
Antibody diluent buffer	12 mL		
ABC diluent buffer	12 mL		
TMB color developing agent	10 mL		
TMB stop solution	10 mL		
Adhesive cover	4 slides		

Storage Instruction

Store at 4°C for 6 months, at -20°C for 12 months. Avoid multiple freeze-thaw cycles.

Materials Required but Not Supplied

- ✓ Microplate reader in standard size.
- ✓ Automated plate washer.
- ✓ Adjustable pipettes and pipette tips. Multichannel pipettes are recommended in the condition of large amount of samples in the detection.
- ✓ Clean tubes and Eppendorf tubes.
- ✓ Washing buffer (neutral PBS or TBS).
- ✓ Preparation of 0.01 M TBS:
- Add 1.2 g Tris, 8.5 g NaCl; 450 μL of purified acetic acid or 700 μL of concentrated hydrochloric acid to 1000 mL H₂O and adjust pH to 7.2-7.6. Finally, adjust the total volume to 1 L.
- ✓ Preparation of 0.01 M PBS:
- Add 8.5 g sodium chloride, 1.4 g Na₂HPO₄ and 0.2 g NaH₂PO₄ to 1000 mL distilled water and adjust pH to 7.2-7.6. Finally, adjust the total volume to 1 L.



Precautions for Use

Please read the following instruction before starting the experiment.

- ✓ To inspect the validity of experiment operation and the appropriateness of sample dilution proportion, pilot experiment using standards and a small number of samples is recommended.
- ✓ The TMB Color Developing agent is colorless and transparent before using, contact us freely if it is not the case.
- ✓ Before using the Kit, spin tubes and bring down all components to the bottom of tubes.
- ✓ Duplicate well assay is recommended for both standard and sample testing.
- ✓ Don't let 96-well plate dry, for dry plate will inactivate active components on plate.
- ✓ Don't reuse tips and tubes to avoid cross contamination.
- ✓ Avoid using the reagents from different batches together.
- ✓ In order to avoid marginal effect of plate incubation due to temperature difference (reaction may be stronger in the marginal wells), it is suggested that the diluted ABC and TMB solution will be pre-warmed in 37°C for 30 min before using.



Assay Protocol

Reagent Preparation

- Reconstitution of the human CXCL9 standard: CXCL9 standard solution should be prepared no more than 2 hours prior to the experiment. Two tubes of CXCL9 standard (10 ng per tube) are included in each kit. Use one tube for each experiment.
 - √ 10,000 pg/mL of human CXCL9 standard solution: Add 1 mL sample diluent buffer into one tube, keep the tube at room temperature for 10 min and mix thoroughly.
 - ✓ 2000 pg/mL of human CXCL9 standard solution: Add 0.2 mL of the above 10 ng/mL CXCL9 standard solution into 0.8 mL sample diluent buffer and mix thoroughly.
 - √ 1000 pg/mL→31.2 pg/mL of human CXCL9 standard solutions: Label 6 Eppendorf tubes with 1000 pg/mL, 500 pg/mL, 250 pg/mL, 125 pg/mL, 62.5 pg/mL, 31.2 pg/mL, respectively. Aliquot 0.3 mL of the sample diluent buffer into each tube. Add 0.3 mL of the above 2000 pg/mL CXCL9 standard solution into 1st tube and mix. Transfer 0.3 mL from 1st tube to 2nd tube and mix. Transfer 0.3 mL from 2nd tube to 3rd tube and mix, and so on.

Note: The standard solutions are best used within 2 hours. The 10 ng/mL standard solution should be stored at 4°C for up to 12 hours, or at -20°C for up to 48 hours. Avoid repeated freeze-thaw cycles.

- Preparation of biotinylated anti-human CXCL9 antibody working solution: The solution should be prepared no more than 2 hours prior to the experiment.
 - ✓ The total volume should be: 0.1 mL/well x (the number of wells). (Allowing 0.1-0.2 mL more than total volume)
 - ✓ Biotinylated anti-human CXCL9 antibody should be diluted in 1:100 with the antibody diluent buffer and mixed thoroughly. . (i.e. Add 1 μL Biotinylated anti-human CXCL9 antibody to 99 μL antibody diluent buffer.)
- Preparation of Avidin-Biotin-Peroxidase Complex (ABC) working solution: The solution should be prepared no more than 1 hour prior to the experiment.
 - ✓ The total volume should be: 0.1 mL/well x (the number of wells). (Allowing 0.1-0.2 mL more than total volume).
 - ✓ Avidin- Biotin-Peroxidase Complex (ABC) should be diluted in 1:100 with the ABC dilution buffer and mixed thoroughly. (i.e. Add 1 µL ABC to 99 µL ABC diluent buffer.)



Sample Preparation

✓ Sample Preparation and Storage

Store samples to be assayed within 24 hours at 2-8°C. For long-term storage, aliquot and freeze samples at -20°C. Avoid repeated freeze-thaw cycles.

- Cell culture supernates: Remove particulates by centrifugation, analyze immediately or aliquot and store at -20°C
- Cell lysates: After sufficient splitting, there should be no obvious cell sediment. Centrifuge cell lysates at approximately 10000 x g for 5 min. collect the cell lysate supernates to go ahead.
- Serum: Allow the serum to clot in a serum separator tube (about 4 hours) at room temperature. Centrifuge at approximately 1000 x g for 15 min. Analyze the serum immediately or aliquot and store samples at -20°C.
- Plasma: Collect plasma using heparin or EDTA as an anticoagulant. Centrifuge for 15 min at 1500 x g within 30 min of collection. Analyze immediately or aliquot and store samples at -20°C.

✓ Sample Dilution Guideline

The user needs to estimate the concentration of the target protein in the sample and select a proper dilution factor so that the diluted target protein concentration falls near the middle of the linear regime in the standard curve. Dilute the sample using the provided diluent buffer. The following is a guideline for sample dilution. Several trials may be necessary in practice. The sample must be well mixed with the diluents buffer.

- ✓ High target protein concentration (20-200 ng/mL). The working dilution is 1:100. i.e. Add 1 μL sample into 99 μL sample diluent buffer.
- ✓ Medium target protein concentration (2-20 ng/mL). The working dilution is 1:10. i.e. Add 10 μL sample into 90 μL sample diluent buffer.
- ✓ Low target protein concentration (31.2-2000 pg/mL). The working dilution is 1:2. i.e. Add 50 μL sample to 50 μL sample diluent buffer.
- ✓ Very Low target protein concentration (0-31.2 pg/mL). No dilution necessary, or the working dilution is 1:2.

Assay Procedure

The ABC working solution, TMB color developing agent and TMB stop solution must be kept warm at 37°C for 30 min before use. When diluting samples and reagents, they must be mixed completely and evenly. Standard CXCL9 detection curve should be prepared for each experiment. The user will decide sample dilution fold by crude estimation of CXCL9 amount in samples.

Aliquot 0.1 mL per well of the 2000 pg/mL, 1000 pg/mL, 500 pg/mL, 250 pg/mL, 125 pg/mL, 62.5 pg/mL, 31.2 pg/mL human CXCL9 standard solutions into the precoated 96-well plate. Add 0.1 mL of the sample diluent buffer into the control well (Zero well). Add 0.1 mL of each properly diluted sample of human cell



culture supernatants, cell lysates, serum, plasma (heparin, EDTA) to each empty well. See "Sample Dilution Guideline" above for details. It is recommended that each human CXCL9 standard solution and each sample be measured in duplicate.

- 2. Seal the plate with a new adhesive cover provided and incubate at 37°C for 90 min.
- 3. Remove the cover, discard plate content, and blot the plate onto paper towels or other absorbent material.

 Do NOT let the wells completely dry at any time.
- 4. Add 0.1 mL of biotinylated anti-human CXCL9 antibody working solution into each well, seal the plate with a new adhesive cover provided and incubate at 37°C for 60 min.
- 5. Wash the plate 3 times with 0.01 M TBS or 0.01 M PBS, and each time let washing buffer stay in the wells for 1 min. Discard the washing buffer and blot the plate onto paper towels or other absorbent material. (Plate Washing Method: Discard the solution in the plate without touching the side walls. Blot the plate onto paper towels or other absorbent material. Soak each well with at least 0.3 mL PBS or TBS buffer for 1~2 minutes. Repeat this process two additional times for a total of THREE washes. *Note: For automated washing, aspirate all wells and wash THREE times with PBS or TBS buffer, overfilling wells with PBS or TBS buffer. Blot the plate onto paper towels or other absorbent material.*)
- 6. Add 0.1 mL of prepared ABC working solution into each well, seal the plate with a new adhesive cover provided and incubate at 37°C for 30 min.
- 7. Wash plate 5 times with 0.01 M TBS or 0.01 M PBS, and each time let washing buffer stay in the wells for 1-2 min. Discard the washing buffer and blot the plate onto paper towels or other absorbent material. (See Step 5 for plate washing method).
- 8. Add 90 μL of prepared TMB color developing agent into each, seal the plate with a new adhesive cover provided and incubate at 37°C in dark for 20-25 min (*Note: For reference only, the optimal incubation time should be determined by end user. And the shades of blue can be seen in the wells with the four most concentrated human CXCL9 standard solutions; the other wells show no obvious color).*
- 9. Add 0.1 mL of prepared TMB stop solution into each well. The color changes into yellow immediately.
- 10. Read the O.D. absorbance at 450 nm in a microplate reader within 30 min after adding the stop solution.

✓ Summary

- Add samples and standards and incubate the plate at 37°C for 90 min. Do not wash.
- Add biotinylated antibodies and incubate the plate at 37°C for 60 min. Wash plate 3 times with 0.01 M
 TBS.
- Add ABC working solution and incubate the plate at 37°C for 30 min. Wash plate 5 times with 0.01 M TBS.
- Add TMB color developing agent and incubate the plate at 37°C in dark for 20-25 min.
- Add TMB stop solution and read.



Data Analysis

Calculation of Results

For calculation, (the relative $O.D._{450}$) = (the $O.D._{450}$ of each well) – (the $O.D._{450}$ of Zero well). The standard curve can be plotted as the relative $O.D._{450}$ of each standard solution (Y) vs. the respective concentration of the standard solution (X). The human CXCL9 concentration of the samples can be interpolated from the standard curve.

Note: If the samples measured were diluted, multiply the dilution factor to the concentrations from interpolation to obtain the concentration before dilution.

Typical Data Obtained from Human CXCL9

(TMB reaction incubate at 37°C for 20-25 min)

Concentration (pg/mL)	0	31.2	62.5	125	250	500	1000	2000
O.D.	0.018	0.057	0.107	0.248	0.408	0.785	1.711	2.308

Performance Characteristics

✓ Range: 31.2 pg/mL – 2000 pg/mL

✓ Sensitivity: < 2pg/mL
</p>

✓ Specificity: Natural and recombinant human CXCL9

✓ Cross-reactivity: There is no detectable cross-reactivity with other relevant proteins.

✓ Precision

Intra-Assay Precision (Precision within an assay)
 Three samples of known concentration were tested on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays)
 Three samples of known concentration were tested in separate assays to assess inter-assay precision.

	Intra	-Assay Preci	sion	Inter-Assay Precision			
Sample	1	2	3	1	2	3	
n	16	16	16	24	24	24	
Mean (pg/mL)	249	834	1573	231	759	1628	
Standard deviation	11.5	35.03	64.5	14.1	63.8	117.2	
CV (%)	4.6	4.2	4.1	6.1	8.4	7.2	



Resources

Reference

- 1. Lee HH, Farber JM (1996). "Localization of the gene for the human MIG cytokine on chromosome 4q21 adjacent to INP10 reveals a chemokine "mini-cluster"". Cytogenet. Cell Genet. 74 (4): 255–8.
- 2. O'Donovan N, Galvin M, Morgan JG (1999). "Physical mapping of the CXC chemokine locus on human chromosome 4". Cytogenet. Cell Genet. 84 (1-2): 39–42.
- 3. Tensen CP, Flier J, Van Der Raaij-Helmer EM, Sampat-Sardjoepersad S, Van Der Schors RC, Leurs R, Scheper RJ, Boorsma DM, Willemze R (1999). "Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3)". J. Invest. Dermatol. 112 (5): 716–22.



Plate Layout

T									
2 C C C C C C C C C C C C C C C C C C C									
2 C C C C C C C C C C C C C C C C C C C	12								
60 00	,								
60 00									
60 00	11								
60									
60									
8	10								
8									
8									
2 3 4 6 9	6								
2 3 4 6 9									
2 3 4 6 9									
2 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	8								
2 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9									
2 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9									
1 2 3 8 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	7								
1 2 3 8 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9									
1 2 3 8 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9									
7	9								
7									
7	2								
1 2 3									
1 2 3									
7	4								
7									
7									
-	3								
-									
-									
	2								
		⋖	В	O	۵	ш	Щ	9	エ